Osstem Implant’s dental unit chairs meet EU medical device rules
Osstem Implant said Thursday it has obtained European Union Medical Device Regulation certification, known as CE MDR, for its dental unit chairs, following certification for its implant products.
The certified models are the K3 and K5, the company said. It described them as flagship products with cumulative global sales of 60,000 units.
A dental unit chair is used to seat or recline patients during treatment and combines multiple small devices and precision parts, requiring advanced development and manufacturing capabilities, the company said.
Osstem Implant launched its first unit chair, the K3, in 2013 under the concept of a “back-to-basics chair.” The company said it designed the height adjustment range and table movement structure for flexibility, aiming for stable usability across different clinical settings.
SK Chemicals launches low-dose triple-combination hypertension drug Telamclo
SK Chemicals said Thursday it has launched Telamclo, a low-dose, triple-combination drug for hypertension.
Telamclo combines telmisartan 20 milligrams, amlodipine 2.5 milligrams and chlorthalidone 6.25 milligrams. SK Chemicals said each ingredient is set at about half the standard dose used in single-ingredient products. The drug was developed in cooperation with Yuhan Corp., which previously marketed Truset tablets with the same ingredients and doses, the company said.
SK Chemicals said the launch reflects a treatment trend toward using drugs with different mechanisms from the early stages of care. It said hypertension involves multiple mechanisms, and single-drug therapy can have limits in controlling blood pressure, driving broader use of combination products.
The company said telmisartan works to inhibit blood vessel constriction, amlodipine helps relax blood vessels, and chlorthalidone regulates the excretion of sodium and water, addressing multiple causes at once.
SK Chemicals said it plans to strengthen its market push by building on synergy with its existing hypertension lineup, including Cosca tablets, and by offering a portfolio spanning single-ingredient and combination therapies.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.